More recently, the Canadian Agency for Drugs and Technologies in Health (CADTH) has updated its treatment algorithm to include consideration of novel therapies in younger, not fit for FCR, high-risk (such as del[17p], TP53-mutated, and IGHV-unmutated) patients with CLL. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.